Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
| Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | ||
| Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | ||
| Simbrinza | Brinzolamide / brimonidine | Glaucoma and ocular hypertension | List | Complete | ||
| Edurant | Rilpivirine | HIV infection | List | Complete | ||
| Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
| ASMANEX | Mometasone furoate | Asthma | List | Complete | ||
| COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete | ||
| Tivicay | Dolutegravir | HIV infection | List | Complete | ||
| Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete |
Last Updated : May 10, 2024